Overview

Biote focuses on hormone optimization using clinically validated medical approaches to identify and treat imbalances in hormone production. It uses lab testing and medical assessment to pinpoint hormone deficiencies or excesses, then prescribes personalized treatment plans—often including bio-identical hormone therapy and related regimens—under medical supervision to restore balanced hormone levels. Biote differentiates itself through its emphasis on translating extensive scientific insight (80+ years of research) into validated protocols and continuing medical oversight, rather than generic supplements. The company’s goal is to help patients achieve balanced hormone levels and improve health outcomes by delivering scientifically grounded, physician-guided hormone optimization.

Simplify's Take

What believers are saying

• Acquired Asteria Health for $8.5M, expanding compounded hormone manufacturing.
• Appointed Robert Peterson CFO on January 8, 2024, strengthening finance leadership.
• Hired John Denne as men's health GM, driving expansion into male hormone therapy.

What critics are saying

• FDA enforcement targets Biote's unsubstantiated compounding claims within 12-24 months.
• UnitedHealth, Anthem, Aetna deny BHRT reimbursement, slashing provider revenues in 6-18 months.
• Texas, California, Florida boards suspend Asteria licenses, disrupting supply chain in 12-24 months.

What makes Biote unique

• Biote Method platform provides education, training, certification, software, and marketing to 7,100 providers.
• Sells sterile pellet insertion kits and branded dietary supplements for hormone optimization.
• Performed over 4 million pellet insertions, proving expertise in precision preventive medicine.

Help us improve and share your feedback! Did you find this helpful?

YesNo

Stock Price